The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, 4, and 7 year follow-up. Multivariate Cox models were stratified by gender and adjusted for sociodemographic characteristics, mental and physical health including vascular risk factors, and genetic vulnerability (apolipoprotein E and cholesteryl ester transfer protein). For women but not men, fibrate use was specifically associated with an increased risk over 7 years of decline in visual memory only (HR=1.29, 95%CI=1.09-1.54, p=0.004), and did not increase risk for incident dementia. This association was independent of genetic vulnerability related to ApoE and Cholesteryl Exchange Transfer Protein polymorphisms and occurred only in women with higher LDL-cholesterol levels and treated with fibrate (HR=1.39, 95%CI=1.08-1.79, p=0.01) and not in those with lower LDL-cholesterol levels irrespective of fibrate treatment. For both sexes, no significant associations were found between statins (irrespective of their lipophilicity) and either cognitive decline or dementia incidence. This prospective study, adjusting for multiple confounders, found no evidence that LLA given in late life reduced the risk of cognitive decline and dementia, but did raise the possibility that women with treatment-resistant high LDL-cholesterol may be at increased risk of decline in visual memory.
INTRODUCTION
Although there is some evidence from experimental studies that lowering cholesterol may slow the expression of Alzheimer's disease (AD), systematic reviews from epidemiological and clinical studies provide, however, little evidence that low cholesterol may be associated with a decrease risk of cognitive decline or AD in the elderly (see for reviews [1, 2] ). Similarly, studies of the potential neuroprotective role of lipid lowering agents (LLA) remain inconclusive [3] . While some studies indicate that statins may moderately reduce risk of Alzheimer's disease risk but not cognitive decline, other studies have been unable to confer this association. Inconsistencies could notably result from heterogeneity in study design, analytic methods, sample size, cognitive evaluation (generally limited to global cognition), and LLA characteristics (e.g. use of statin vs.
non-statin LLA, and lipophilicity influencing capacity to cross the blood brain barrier), with very few studies specifically examining fibrates. A common problem has been failure to take into account the numerous potential vascular confounders for cognitive decline. Of particular importance is the clinical context in which lipid treatment occurs; statins being generally prescribed in the first instance for the management of low density lipoprotein-cholesterol (LDL-cholesterol), whereas fibrate prescription generally following statin treatment failure, intolerance, or in cases of atherogenic dyslipidemia [4] . This point needs to be taken into account in clinical analyses as persons receiving fibrates are therefore likely to constitute a separate clinical sub-group from those receiving statins.
Genetic vulnerability has not been systematically considered despite a possible interactive effect between lipid levels and apolipoprotein E (ApoE). Surprisingly, cholesteryl ester transfer protein has not been examined although it is not only involved in the aetiology of atherogenic dyslipidemia phenotype but has also been associated with slower memory decline and lower incident dementia [5] . Cholesteryl Exchange Transfer Protein promotes the exchange of triglycerides for cholesteryl ester in lipoprotein, and statin and fibrate may inhibit its activity.
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Cognitive measures and dementia
The Isaacs Set Test provided a measure of verbal fluency or semantic access (number of items produced within 30 seconds), the Benton Visual Retention Test assessed visual memory, the Trail Making Tests (TMT) A and B psychomotor speed and executive function respectively and the Mini Mental State Examination (MMSE) was used as a global measure of cognitive function [10] . All tests were administered at baseline, and waves 1, 2, and 3 of the follow-up, except the TMT which was not given in wave 1.
A three-step procedure was used to diagnose cases of dementia [10] . First, screening was based on a thorough neuropsychological examination by trained psychologists (see above). Data on activities of daily living, severity of cognitive disorders, and, where possible, magnetic resonance images or computed tomography scans were collected. In addition, in Montpellier and Bordeaux all participants were examined by a neurologist. In Dijon only persons suspected of having a cognitive deficit on the basis of their neuropsychological performance underwent further examination by a specialist. Finally, in the 3 centers, all suspected dementia cases were analyzed by a common independent committee of neurologists according to DSM-IV [11] criteria. This committee reviewed all potential cases of dementia to obtain a consensus on its diagnosis and etiology based on all available information. Alzheimer's disease was diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria. The onset of dementia was the date of the follow-up interview when dementia was diagnosed.
Socio-demographic and clinical variables
The standardized interview included questions on socio-demographic and lifestyle characteristics with evaluation of hypertension and diabetes as well as an inventory of all drugs (including LLA and anticholinergic drugs as defined previously [12] ) used over the preceding month. Medical prescriptions and the medications themselves were checked by the interviewer.
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History of ischemic pathologies (stroke, angina pectoris, myocardial infarction and cardio-vascular surgery) and chronic respiratory disorders were established according to standardized questions.
Depressive symptomatology was assessed by the Center for Epidemiological Studies-Depression Scale (CES-D) [13] with a 16 cut-off point. Venous blood samples were taken at baseline from subjects after fasting for >12h. Lipid levels were evaluated in serum by routine enzymatic methods [7] and genotyping of ApoE and Cholesteryl Exchange Transfer Protein (rs1800775 and rs5882 polymorphisms) was performed.
Statistical analyses
The Chi2 test for categorical variables and the Student t test for continuous variables were used to identify treatment group differences. Cognitive decline was evaluated over the 7-year follow-up period. The score distribution being not normal for the use of criteria based on standard deviation, cognitive decline was defined as being in the first quintile of the distribution of the differences, i.e. in the worst quintile. More specifically, a difference score was first calculated between cognitive scores obtained at any follow-up and the baseline score. The number of difference scores for a given subject thus depended on the number of follow-ups he/she had data for, from only one difference (the subject was only followed up once in the 7-year period) up to 3 differences (the subject had data on each follow-up). The quintile of the individual maximum of the difference scores was then calculated. The group of decliners was then defined as those participants belonging to the worst quintile of the worst difference scores and the time of decline was the first visit when the subject fell below the cut-off. Decliners were thus defined as persons having decreased from baseline by at least 3 points on the MMSE or on the Benton test or at least 10 points on the Isaacs test and an increase of at least 22 seconds on the TMTA or 57 seconds on the TMTB. Cox proportional hazards models with delayed entry taking age as the basic time scale and birth as the time origin [14] were used to determine whether baseline LLA use was associated with risks of cognitive decline and dementia incidence. This model enabled to take into account the full inserm-00707350, version 1 -12 Jun 2012 information until time of censoring, either by death or loss to follow-up, or the time of observed cognitive decline (or dementia), thus minimizing selection bias due to cohort attrition. After gender stratification, Hazard Ratios (HRs) were adjusted for centre, educational level, and baseline cognitive performance in addition to age, which was already taken into account in the model (minimally adjusted model 0). Multivariate analyses further included selected covariates associated with cognitive decline (at p<0.15), namely marital status, body mass index (BMI), mobility, as well as alcohol intake for men and anticholinergic use, depression, chronic respiratory disorders, and hormone treatment for women (model 1). Final multi-adjusted models were further adjusted for ischemic pathologies, diabetes, hypertension, LDL-cholesterol and triglyceride levels (categorized into quartiles), APOE4, and Cholesteryl Exchange Transfer Protein for both gender (model 2). For incident dementia, the analysis was undertaken on 7056 subjects without missing data for baseline adjustment variables but with possibly missing repeated cognitive testing. Analyses were carried out using SAS software (version 9.2) with a significant level of p <0.05. In the Tables, we reported data without correcting for multiple testing as we consider Bonferroni adjustment to be overly conservative given that the cognitive tests independently explore different aspects of cognitive functioning involving different cerebral areas (see the Discussion section).
RESULTS
Subject characteristics
Within this elderly community-dwelling sample, 936 of the 6830 subjects (13.7%) were taking fibrates at baseline and 1119 (16.4%) statins. No subjects were taking nicotinic acid and derivatives and only 11 subjects were taking bile acid sequestrants. Fibrates consisted of fenofibrate (72.0% of fibrates), ciprofibrate (15.7%), bezafibrate (9.6%) and gemfibrozil (2.7%). The lipophilic statins were simvastatin (36.7% of statins), cerivastatin (15.0%) and lovastatin (0.1%) and hydrophilic statin were pravastatin (26.9%), atovastatin (17.5%) and fluvastatin (3.8%). Women were more frequent fibrate users (14.9%) than men (11.8%, p=0.001). For both men and women,
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LLA use was higher in subjects overweight, with ischemic pathologies, diabetes, high blood pressure, low LDL-cholesterol levels, and carrying ApoE4 allele (p<0.005) ( Table 1) . Men with higher triglyceride levels but women with lower triglyceride levels were more frequent LLA users (p<0.001), whereas women using LLA had less frequently chronic respiratory disorders (p=0.01).
There was no significant association between LLA use and other non-vascular factors more related to general health such as depressive symptoms, mobility, and use of drugs with anticholinergic properties.
LLA use and cognitive decline
Cox models adjusted for age, center, education level and baseline cognitive performance indicated that women taking fibrates but not statins at baseline showed greater decline over 7 years on the Benton visual recall test (HR=1.24, 95%CI=1.05-1.46, p=0.04) ( Table 2 
Dementia incidence
Within the 7056 subjects included in the analysis, 483 incident cases of all dementias were diagnosed during the 7-year follow-up, of whom 332 had Alzheimer's disease (AD). Adjusted Cox models failed to find a significant association between fibrate or statin use at baseline and the incidence of dementia or AD in women or men ( Table 3) .
DISCUSSION
Our results indicate a significant 1.3-fold increased risk of decline in visual memory in elderly women treated with fibrates at baseline or continuously during the 7-year follow-up. The same results were obtained in the minimally and the fully adjusted model, which was able to take into account multiple co-determinants of cognitive decline, including pathologies associated with LLA treatment and genetic vulnerability related to both lipid levels and cognitive decline and dementia (e.g. ApoE and Cholesteryl Exchange Transfer Protein). It should be noted that baseline global cognitive functioning was not significantly different between LLA users and non users and the same results were obtained in minimally and fully adjusted models for cognitive scores and incident dementia which suggests that an indication bias in which LLA prescribed for patients at higher risk of dementia could have confounded the associations would be highly unlikely. The association between fibrate use and decline in visual memory remained significant even after applying the conservative Bonferroni correction for multiple comparisons (2 genders x 2 LLA types, p <0.0125).
No significant association between statin or fibrate use and cognitive decline was observed in men.
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There was no significant association between fibrate use at baseline and risk of developing dementia or AD over 7-years in men or women.
Very few studies have evaluated the specific effect of fibrates on cognitive function; being generally assimilated with other LLA (e.g. bile-acid binding resins or nicotinic acid and derivatives)
as "non-statin cholesterol-lowering drugs" which collectively have been reported as having no significant association with dementia incidence [15] [16] [17] [18] although one study reports an association in younger elderly subjects only [19] . In the present study, we found that only women with both relatively high LDL-cholesterol levels (> 3.1 mmol/l) and taking fibrates were at higher risk for cognitive decline in visual memory but not those with lower LDL-cholesterol levels. This notably precludes a neurotoxic effect of fibrate per se. Fibrates and statins differ by their mechanism of action. Statins inhibit hydroxymethylglutaryl-CoA reductase the rate-limiting step in cholesterol biosynthesis producing a lowering of LDL-cholesterol levels. Fibrates are agonists for the nuclear transcription factor peroxisome proliferator-activated receptor-alpha with effects on ApoA-I, A-II, and C-III, lipoprotein lipase, and fatty acid oxidation, notably leading to a number of antiatherogenic effects including triglyceride lowering and HDL-cholesterol increase. In various animal models, neuronal and vascular protective effects of fibrate have been reported which have recently been related to their capacity to modulate oxidative stress and inflammation [20, 21] . The negative effect found in this study on cognitive decline in visual memory may thus reflect a more severe form of hypercholesterolemia persisting despite fibrate treatment, considering that statin is generally the first-line drug to achieve LDL-cholesterol treatment goals, whereas fibrate prescription would only generally follow statin treatment failure or intolerance or elevated triglyceride levels and atherogenic dyslipidemia [4] . The association between decline in visual memory and fibrate use remained significant after controlling for triglycerides, vascular factors, and genetic vulnerability. We cannot exclude however, the possibility that asymptomatic subclinical atherosclerosis could be involved to confound this association. The specific effect observed in inserm-00707350, version 1 -12 Jun 2012 elderly women treated with fibrate remains to be explained but may involve pharmacodynamic or metabolism properties as well as differences in patterns of vascular risk factors and lipid lowering capacity which can be modulated by hormonal status [4, 7] . Current hormonal treatment is known to be associated with decreased LDL-cholesterol levels in postmenopausal women [7] . Hormonal treatment was also found to be specifically associated with better visual memory in the large Women's Health Initiative Memory Study randomized controlled trial [22] as well as in a subgroup of women of the 3C study [23] . Whether women with treatment-resistant high LDL-cholesterol and not treated with hormonal treatment may be at increased risk of decline in visual memory remains to be further examined.
For statins, we only observed non significant associations with cognitive function in the minimally adjusted models but not in the fully adjusted model, suggesting that this was more likely related to the underlying burden of vascular illness rather than the statin itself (indication bias) [24, 25] . The absence of effect of statins on cognitive decline is in agreement with a number of clinical and epidemiological studies. Two large randomized controlled trials conducted in mid-to late-life adults at high risk for vascular disease did not show differential effect on cognitive function of the lipophilic simvastatin and the hydrophilic pravastatin which were taken by 64% of our sample [26] [27] [28] . Two prospective cohort studies reported a significant negative association between global cognition and dementia and statin use, but it was not adjusted for baseline cognitive performance, lipid levels, and/or vascular pathologies [29, 30] . Regarding incident AD, several prospective cohort studies did not find significant associations even when considering lipophilicity [17, 18, 31] . A cohort study reported a significant negative association after 9.2 years of follow-up independent of statin lipophilicity but it did not consider lipid components as confounders [16] . A negative association was recently reported in early old but not the very old [32] . No large randomized controlled trials with statins have so far reported an AD preventive effect [26, 28] , nor an effect on AD evolution [33, 34] .
A limitation of our study could have been the exclusion of participants, those lost to follow-up being more likely to have cognitive decline or dementia, low education level, to be older, and thus with worse physical and mental health. This may limit the generalizability of our results, and associations may have thus been underestimated. We did not consider treatment compliance, which may have caused classification bias. We did not have information on the reasons for prescribing fibrate or on precise initiation time and duration of medication use, which could not definitively address the question of the modifying role of prolonged use and of midlife optimal therapeutic window. We cannot exclude the possibility that there are other unknown factors including subclinical disease in addition to that detectable through the analysis of lipids, glycemia, and hypertension, which may confound the associations.
The strengths of this study relate to its prospective, community-based design, large size, and extensive information obtained on clinical status. LLA use was ascertained, thus minimizing exposure misclassification and evaluated at baseline and throughout the 7-year follow-up. We could examine separately fibrates and statins as well as statin lipophilicity related to blood brain barrier permeability. Finally, we have taken into account a wide range of competing causes of cognitive dysfunction in the elderly, notably lifestyle, genetic, and health covariates especially those related to vascular disorders, thus limiting any potential confounding including prescription bias. We excluded cases of prevalent dementia from the analyses and were able to distinguish AD from other forms of dementia using a validated clinical diagnosis of dementia.
In conclusion, our study, adjusting for multiple confounders, found no evidence that LLA given in late life reduced the risk over 7 years of cognitive decline and incident dementia. It may on the other hand suggest that elderly women with treatment-resistant high LDL-cholesterol may be at increased risk of decline in visual memory, for which women were reported to be less resistant to insult and ageing than in verbal skills [35] Further studies with a more comprehensive battery of inserm-00707350, version 1 -12 Jun 2012 cognitive tests are required to determine whether this risk is indeed specific to visual memory or may be observed in other areas of information processing. Whether these women constitute a subgroup which has given rise to cognitive compromise or even a pre-dementia syndrome perhaps decades before dementia diagnosis, remains to be evaluated. c The presence of depressive symptoms was assessed using the Center for Epidemiological StudiesDepression Scale [13] with a cut-off of >16.
d Chronic respiratory disorders including corticosteroid drug intake and self-reported bronchitis, wheezing, tachypnea, and asthma attacks (over the last 12months).
e History of stroke, myocardial infarction, angina pectoris, or arteritis and cardio-vascular surgery f Diabetes defined as glucose ≥7 mmol/l or treated. g High blood pressure defined as ≥160/95 mm Hg or treated. h Mean (SD) except for triglycerides (geometric mean). years. This analysis was undertaken on 7056 subjects without missing data for baseline adjustment variables but with possibly missing repeated cognitive testing; 290 women and 193 men were diagnosed with incident dementia, of whom 206 women and 126 men had incident Alzheimer's disease. The 110 women and 87 men with other types of dementia (of whom 21 men and 22 women with vascular dementia) were excluded from the analysis of Alzheimer's disease.
b Adjusted for age (time scale), centre, and education (model 0).
